Wyeth Delayed Pondimin Label Revision Pending Redux Review, Plaintiffs Say
Executive Summary
Wyeth-Ayerst stalled a labeling revision for the company's diet drug Pondimin (fenfluramine) until FDA completed its NDA review of the company's related diet drug Redux NDA, plaintiffs' attorneys in the N.J. fen-phen class action suit Vadino, Varalli, and DeBerardinis v. American Home Products maintain.